These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8257144)

  • 41. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs.
    Walker RD; Stein GE; Hauptman JG; MacDonald KH; Budsberg SC; Rosser EJ
    Am J Vet Res; 1990 Jun; 51(6):896-900. PubMed ID: 2195927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
    Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects.
    Orlando PL; Barriere SL; Hindler JA; Frost RW
    Diagn Microbiol Infect Dis; 1990; 13(2):93-7. PubMed ID: 2114954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
    Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
    James JK; Palmer SM; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humours of patients by different topical application modes.
    von Keyserlingk J; Beck R; Fischer U; Hehl EM; Guthoff R; Drewelow B
    Eur J Clin Pharmacol; 1997; 53(3-4):251-5. PubMed ID: 9476040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.
    Standiford HC; Drusano GL; Forrest A; Tatem B; Plaisance K
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1177-82. PubMed ID: 3631942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.
    Brittain DC; Scully BE; McElrath MJ; Steinman R; Labthavikul P; Neu HC
    J Clin Pharmacol; 1985 Mar; 25(2):82-8. PubMed ID: 3157705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum inhibitory and bactericidal activity of ciprofloxacin following intravenous administration.
    Dudley MN; Mandler HD; Mayer KH; Zinner SH
    DICP; 1989 Jun; 23(6):456-60. PubMed ID: 2741478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa.
    Smith RP; Baltch AL; Franke MA; Michelsen PB; Bopp LH
    J Antimicrob Chemother; 2000 Apr; 45(4):483-8. PubMed ID: 10747825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance studies with ofloxacin.
    Foxall PA; Felmingham D; Grüneberg RN
    J Chemother; 1989 Jul; 1(4 Suppl):381-3. PubMed ID: 16312450
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
    Bowker KE; Wootton M; Rogers CA; Lewis R; Holt HA; MacGowan AP
    J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.